6-(4-hydroxyphenyl)-3,4-dihydronaphthalen-1(2H)-one | 101110-09-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 6-(4-hydroxyphenyl)-3,4-dihydronaphthalen-1(2H)-one
• 英文别名: 6-(4'-hydroxyphenyl)-1-tetralone；6-(4-hydroxyphenyl)-1-tetralone；6-(4-hydroxy-phenyl)-3,4-dihydro-2H-naphthalen-1-one；6-(4-Hydroxy-phenyl)-3,4-dihydro-2H-naphthalin-1-on；6-(4-hydroxyphenyl)-3,4-dihydro-2H-naphthalen-1-one
• CAS: 101110-09-2
• 化学式: C₁₆H₁₄O₂
• 分子量: 238.286
• InChiKey: NBXFNIUSTYUSRR-UHFFFAOYSA-N

物化性质

• 熔点：
  208-211 °C
• 沸点：
  444.1±34.0 °C(Predicted)
• 密度：
  1.212±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6-(4-hydroxyphenyl)-3,4-dihydronaphthalen-1(2H)-one 在 钯 4-异丙基甲苯 作用下， 生成 6-(4'-hydroxyphenyl)-1-naphthol
  参考文献：
  名称：

  Substituted phenyl naphthalenes as estrogenic agents

  摘要：

  这项发明提供了具有结构的式I的雌激素受体调节剂 1 其中 R 1 ，R 2 ，R 3 ，R 4 ，R 5 ，R 6 ，R 7 ，R 8 ，R 9 和R 10 如规范中所定义，或其药用可接受盐。

  公开号：

  US20030181519A1
• 作为产物：
  描述：

  6-羟基-1-四氢萘酮 在 吡啶 、 四(三苯基膦)钯 、 sodium carbonate 作用下， 以 乙二醇二甲醚 、 二氯甲烷 为溶剂， 反应 0.5h， 生成 6-(4-hydroxyphenyl)-3,4-dihydronaphthalen-1(2H)-one
  参考文献：
  名称：

  ERβ Ligands. 3. Exploiting Two Binding Orientations of the 2-Phenylnaphthalene Scaffold To Achieve ERβ Selectivity

  摘要：

  The 2-phenylnaphthalene scaffold was explored as a simplified version of genistein in order to identify ER selective ligands. With the aid of docking studies, positions 1, 4, and 8 of the 2-phenylnaphthalene template were predicted to be the most potentially influential positions to enhance ER selectivity using two different binding orientations. Both orientations have the phenol moiety mimicking the A-ring of genistein. Several compounds predicted to adopt orientations similar to that of genistein when bound to ERbeta were observed to have slightly higher ER affinity and selectivity than genistein. The second orientation we exploited, which was different from that of genistein when bound to ERbeta, resulted in the discovery of several compounds that had superior ER selectivity and affinity versus genistein. X-ray structures of two ER selective compounds (i.e., 15 and 47) confirmed the alternate binding mode and suggested that substituents at positions 1 and 8 were responsible for inducing selectivity. One compound (i.e., 47, WAY-202196) was further examined and found to be effective in two models of inflammation, suggesting that targeting ER may be therapeutically useful in treating certain chronic inflammatory diseases.

  DOI：

  10.1021/jm058173s

文献信息

• Substituted phenyl naphthalenes as estrogenic agents
  申请人：Wyeth

  公开号：US20030181519A1

  公开（公告）日：2003-09-25

  This invention provides estrogen receptor modulators of formula I, having the structure 1 wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , and R 10 , are as defined in the specification, or a pharmaceutically acceptable salt thereof.

  这项发明提供了具有结构的式I的雌激素受体调节剂 1 其中 R 1 ，R 2 ，R 3 ，R 4 ，R 5 ，R 6 ，R 7 ，R 8 ，R 9 和R 10 如规范中所定义，或其药用可接受盐。
• Synthesis and Biological Evaluation of Spiro-δ-lactones as Inhibitors of 17β-Hydroxysteroid Dehydrogenase Type 2 (17β-HSD2)
  作者：Kuiying Xu、Marie Wetzel、Rolf W. Hartmann、Sandrine Marchais-Oberwinkler

  DOI：10.2174/157018011795514230

  日期：2011.6.1

  17β-Hydroxysteroid dehydrogenase type 2 (17β-HSD2) catalyzes the oxidation of the potent estradiol (E2) to the less active estrogen estrone (E1). Inhibitors of this enzyme should maintain the local level of E2 in bone tissue when the E2 concentration in the circulation drops and therefore might be useful for the treatment of osteoporosis. In this work, novel non-steroidal spiro-δ-lactone compounds

  17β-羟基类固醇脱氢酶2（17β-HSD2）催化强效雌二醇（E2）氧化为活性较低的雌激素雌酮（E1）。当循环中的E2浓度下降时，该酶的抑制剂应维持骨组织中E2的局部水平，因此可能对治疗骨质疏松症有用。在这项工作中，合成了设计为17β-HSD2抑制剂的新型非甾体螺-δ-内酯化合物，并研究了它们的理化和生物学特性。这些新的螺-δ-内酯对于进一步开发而言不够稳定，并且对酶的抑制作用很低。
• COMPOUND
  申请人：VICKER Nigel

  公开号：US20090186900A1

  公开（公告）日：2009-07-23

  There is provided a compound of Formula I wherein the various symbols are as defined in the description, and a method of manufacturing a medicament for use in the therapy of a condition or disease associated with 17β-hydroxysteroid dehydrogenase (17β-HSD), comprising a compound of Formula I.

  提供了一种式子为I的化合物，其中各符号的定义如说明书所述，并提供一种制造药物的方法，用于治疗与17β-羟基类固醇脱氢酶（17β-HSD）相关的疾病或病症，包括化合物I。
• WO2007/96647
  申请人：——

  公开号：——

  公开（公告）日：——
• Novel inhibitors of 17β-hydroxysteroid dehydrogenase type 1: Templates for design
  作者：Gillian M. Allan、Nigel Vicker、Harshani R. Lawrence、Helena J. Tutill、Joanna M. Day、Marion Huchet、Eric Ferrandis、Michael J. Reed、Atul Purohit、Barry V.L. Potter

  DOI：10.1016/j.bmc.2008.02.059

  日期：2008.4

  The 17 beta-hydroxysteroid dehydrogenases (17 beta-HSDs) catalyze the interconversion between the oxidized and reduced forms of androgens and estrogens at the 17 position. The 17 beta-HSD type 1 enzyme (17 beta-HSD1) catalyzes the reduction of estrone (E1) to estradiol and is expressed in malignant breast cells. Inhibitors of this enzyme thus have potential as treatments for hormone dependent breast cancer. Syntheses and biological evaluation of novel non-steroidal inhibitors designed to mimic the E1 template are reported using information from potent steroidal inhibitors. Of the templates investigated biphenyl ethanone was promising and led to inhibitors with IC50 values in the low micromolar range. (C) 2008 Elsevier Ltd. All rights reserved.